Depletion of antigen-presenting cells by clodronate liposomes reverses the psoriatic skin phenotype in KC-Tie2 mice

British Journal of Dermatology

Volumn 164, Issue 4, 2011, Pages 750-758

  Ward, Nicole L ^a,b   Loyd, C M ^a   Wolfram, J A ^a   Diaconu, D ^a   Michaels, C M ^a   McCormick, T S ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLODRONIC ACID; GAMMA INTERFERON; GLYCOPROTEIN P 15095; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 23; INTERLEUKIN 6; LIPOSOME; TUMOR NECROSIS FACTOR ALPHA;

ACANTHOSIS; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG DELIVERY SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; SKIN;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD; BONE DENSITY CONSERVATION AGENTS; CLODRONIC ACID; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRADERMAL; LIPOSOMES; MICE; MICE, KNOCKOUT; NEOVASCULARIZATION, PHYSIOLOGIC; PHENOTYPE; POLYMERASE CHAIN REACTION; PSORIASIS; SKIN;

EID: 79953726733     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.10129.x     Document Type: Article

References (44)

1. Bata-Csorgo Z, Hammerberg C, Voorhees JJ et al. Intralesional T-lymphocyte activation as a mediator of psoriatic epidermal hyperplasia. J Invest Dermatol 1995; 105 (Suppl.):89S-94S.
2. Strange P, Cooper KD, Hansen ER et al. T-lymphocyte clones initiated from lesional psoriatic skin release growth factors that induce keratinocyte proliferation. J Invest Dermatol 1993; 101:695-700. (Pubitemid 23322026)
3. Volpe E, Servant N, Zollinger R et al. A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol 2008; 9:650-7. (Pubitemid 351712635)
4. Kryczek I, Bruce AT, Gudjonsson JE et al. Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. J Immunol 2008; 181:4733-41.
5. Zheng Y, Danilenko DM, Valdez P et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007; 445:648-51. (Pubitemid 46232884)
6. Blauvelt A. T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis. J Invest Dermatol 2008; 128:1064-7. (Pubitemid 351543223)
7. Fitch E, Harper E, Skorcheva I et al. Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep 2007; 9:461-7. (Pubitemid 350305203)
8. Lowes MA, Chamian F, Abello MV et al. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci USA 2005; 102:19057-62. (Pubitemid 43049565)
9. Zhu KJ, Cheng H, Mao XH et al. Increased endocytic activity in monocyte-derived dendritic cells in patients with psoriasis vulgaris. Indian J Med Res 2006; 123:43-50.
10. Lee E, Trepicchio WL, Oestreicher JL et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004; 199:125-30. (Pubitemid 38076484)
11. Wang F, Lee E, Lowes MA et al. Prominent production of IL-20 by CD68+/CD11c+ myeloid-derived cells in psoriasis: gene regulation and cellular effects. J Invest Dermatol 2006; 126:1590-9.
12. Xia YP, Li B, Hylton D et al. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 2003; 102:161-8. (Pubitemid 36759650)
13. Cheng J, Turksen K, Yu QC et al. Cachexia and graft-vs.-host-disease-type skin changes in keratin promoter-driven TNF-alpha transgenic mice. Genes Dev 1992; 6:1444-56.
14. Cook PW, Pittelkow MR, Piepkorn M. Overexpression of amphi-regulin in the epidermis of transgenic mice induces a psoriasis-like cutaneous phenotype. J Invest Dermatol 1999; 113:860 (Letter).
15. Carroll JM, Crompton T, Seery JP et al. Transgenic mice expressing IFN-gamma in the epidermis have eczema, hair hypopigmentation, and hair loss. J Invest Dermatol 1997; 108:412-22. (Pubitemid 27148275)
16. Groves RW, Mizutani H, Kieffer JD et al. Inflammatory skin disease in transgenic mice that express high levels of interleukin 1 alpha in basal epidermis. Proc Natl Acad Sci USA 1995; 92:11874-8. (Pubitemid 26014212)
17. Groves RW, Rauschmayr T, Nakamura K et al. Inflammatory and hyperproliferative skin disease in mice that express elevated levels of the IL-1 receptor (type I) on epidermal keratinocytes. Evidence that IL-1-inducible secondary cytokines produced by keratinocytes in vivo can cause skin disease. J Clin Invest 1996; 98:336-44. (Pubitemid 26255731)
18. Zenz R, Eferl R, Kenner L et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 2005; 437:369-75. (Pubitemid 41613493)
19. Wang H, Peters T, Kess D et al. Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasiform skin inflammation. J Clin Invest 2006; 116:2105-14. (Pubitemid 44162319)
20. Stratis A, Pasparakis M, Rupec RA et al. Pathogenic role for skin macrophages in a mouse model of keratinocyte-induced psoriasislike skin inflammation. J Clin Invest 2006; 116:2094-104. (Pubitemid 44162318)
21. Li AG, Wang D, Feng XH et al. Latent TGFbeta1 overexpression in keratinocytes results in a severe psoriasis-like skin disorder. EMBO J 2004; 23:1770-81. (Pubitemid 38649640)
22. Gottlieb AB, Matheson RT, Lowe N et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139:1627-32; discussion 32.
23. Leonardi CL, Powers JL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349:2014-22. (Pubitemid 37448924)
24. Krueger GG, Langley RG, Leonardi C et al. A human interleukin- 12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007; 356:580-92. (Pubitemid 46220818)
25. Toichi E, Torres G, McCormick TS et al. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol 2006; 177:4917-26. (Pubitemid 44469828)
26. Kauffman CL, Aria N, Toichi E et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol 2004; 123:1037-44. (Pubitemid 39586823)
27. Wolfram JA, Diaconu D, Hatala DA et al. Keratinocyte but not endothelial cell specific overexpression of Tie2 leads to the development of psoriasis. Am J Pathol 2009; 174:1443-58.
28. Jones N, Voskas D, Master Z et al. Rescue of the early vascular defects in Tek/Tie2 null mice reveals an essential survival function. EMBO Rep 2001; 2:438-45. (Pubitemid 32509961)
29. Diamond I, Owolabi T, Marco M et al. Conditional gene expression in the epidermis of transgenic mice using the tetracycline-regulated transactivators tTA and rTA linked to the keratin 5 promoter. J Invest Dermatol 2000; 115:788-94.
30. Van Rooijen N, Sanders A, Van den Berg TK. Apoptosis of macrophages induced by liposome-mediated intracellular delivery of clodronate and propamidine. J Immunol Methods 1996; 193:93-9.
31. Calin MV, Manduteanu I, Dragomir E et al. Effect of depletion of monocytes/macrophages on early aortic valve lesion in experimental hyperlipidemia. Cell Tissue Res 2009; 336:237-48.
32. Ylitalo R, Syvala H, Tuohimaa P et al. Suppression of immunoreactive macrophages in atheromatous lesions of rabbits by clodronate. Pharmacol Toxicol 2002; 90:139-43. (Pubitemid 34289611)
33. Wang H, Peters T, Sindrilaru A et al. Key role of macrophages in the pathogenesis of CD18 hypomorphic murine model of psoriasis. J Invest Dermatol 2009; 129:1100-14.
34. Nickoloff BJ, Xin H, Nestle FO et al. The cytokine and chemokine network in psoriasis. Clin Dermatol 2007; 25:568-73. (Pubitemid 350103656)
35. Nickoloff BJ. Cracking the cytokine code in psoriasis. Nat Med 2007; 13:242-4. (Pubitemid 46376653)
36. Pasparakis M, Courtois G, Hafner M et al. TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2. Nature 2002; 417:861-6. (Pubitemid 34670334)
37. Antoni C, Krueger GG, de Vlam K et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005; 64:1150-7. (Pubitemid 41113349)
38. Antoni CE, Kavanaugh A, Kirkham B et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005; 52:1227-36. (Pubitemid 40530131)
39. Gottlieb AB, Evans R, Li S et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004; 51:534-42. (Pubitemid 39278071)
40. Mease PJ, Kivitz AJ, Burch FX et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004; 50:2264-72. (Pubitemid 38924405)
41. Carlin CS, Feldman SR, Krueger JG et al. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol 2004; 50:859-66. (Pubitemid 38691110)
42. Beuthien W, Mellinghoff HU, von Kempis J. Skin reaction to adalimumab. Arthritis Rheum 2004; 50:1690-2. (Pubitemid 38608093)
43. Papp KA, Langley RG, Lebwohl M et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371:1675-84. (Pubitemid 351671884)
44. Wolfram J, Diaconu D, Tessier P et al. Antigen presenting cell depletion in the KC-Tie2 mouse model of psoriasis attenuates acanthosis, angiogenesis and leads to decreases in IL-23 and S100A8/9 but not IL-12. J Invest Dermatol 2009; 129:S122.